Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial Meeting Abstract
| Authors: | Eskander, R. N.; Sill, M.; Miller, A.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M. S.; Canturia, G.; Girda, E.; Mathews, C.; Kavecansky, J.; Leath, C. A. 3rd; Gien, L.; Hinchcliff, E.; Lele, S.; Powell, M. A.; Aghajanian, C. |
| Abstract Title: | Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1284 |
| Language: | English |
| ACCESSION: | WOS:001087480203523 |
| DOI: | 10.1016/j.annonc.2023.10.037 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA43 -- Source: Wos |
